Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23419880 | 1.00 | SLC1A1 (0.39) | SLC1A1DDAH1LTA4HCA1CA2 | |
| SCHEMBL8348754 | 1.00 | SLC1A1 (0.39) | SLC1A1DDAH1LTA4HCA1CA2 | |
| Hydrochloric Acid SCHEMBL29262795 | 0.98 | SLC1A1 (0.38) | SLC1A1DDAH1LTA4HCA1CA2 | |
| Hydrochloric Acid SCHEMBL29262798 | 0.98 | SLC1A1 (0.38) | SLC1A1DDAH1LTA4HCA1CA2 | |
| SCHEMBL806697 | 0.87 | DDAH1 (0.42) | SLC1A1DDAH1LTA4HCA1CA2 | |
| SCHEMBL11776470 | 0.85 | SMN1; SMN2 (0.42) | SLC1A1LTA4HCA1CA2SMN1; SMN2 | |
| SCHEMBL7365991 | 0.85 | DDAH1 (0.41) | DDAH1LTA4HCA1CA2ZDHHC7 | |
| SCHEMBL8348874 | 0.84 | NOS3 (0.37) | SLC1A1DDAH1LTA4HCA1CA2 | |
| SCHEMBL3379701 | 0.83 | ALOX15 (0.42) | SLC1A1LTA4HCA1CA2SMN1; SMN2 | |
| SCHEMBL21101262 | 0.83 | ALOX15 (0.42) | SLC1A1LTA4HCA1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-4215525-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | PARION SCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9849129-B2 | Sodium channel blockers for skin disorders | PARION SCIENCES, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-1030835-B1 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| US-6344570-B1 | ANTISTICKING AGENTS FOR CELLS | ASTRAZENECA UK LIMITED (GB) | 2002-02-05 | — | — | US | disclosed |
| CN-1278790-A | Chemical compound | ASTRA ZENECA BRITISH INC (GB) | 2001-01-03 | — | — | CN | disclosed |
| EP-1030835-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024398-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092915-A1 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS | SCNN1B, SCNN1A, SCNN1G | SLC1A1 279/4885DDAH1 693/4885LTA4H 214/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | SLC1A1 2367/4885DDAH1 2630/4885LTA4H 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.